<DOC>
	<DOCNO>NCT01350960</DOCNO>
	<brief_summary>The purpose study Safety Tolerability .</brief_summary>
	<brief_title>Multiple Ascending Dose Study SPC5001 Treatment Healthy Subjects Subjects With FH</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>1 . Healthy male female subject subject heterozygous Familial Hypercholesterolemia Healthy male female subject , age 18 65 year , inclusive enrol Cohorts 1 4 . In Cohort 5 , male female subject heterozygous Familial Hypercholesterolemia , confirm genetic testing , without history cardiovascular disease ( e.g . coronary artery , peripheral artery cerebrovascular disease ) , hypertension diabetes mellitus age 1845 year , inclusive , enrol . 2 . BMI 1833 kg/m2 3 . Screening hematology , clinical chemistry , coagulation urinalysis consistent overall good health follow criterion meet : LDL ≥.3.24 mmol/L ( ≥ 100 mg/dL ) Triglycerides ( fast ) &lt; 4.5 mmol/L ( &lt; 398 mg/dL ) ALT within normal limit healthy subject ALT &lt; 2 x ULN FH subject 1 . Any uncontrolled active major systemic disease include , limited : cardiovascular , pulmonary , gastrointestinal , metabolic , urogenital , neurological , immunological , psychiatric , neoplastic disorder metastatic potential History presence malignancy within past year exclusion criterion . Subjects successfully treat recurrence basal cell carcinoma skin carcinoma insitu cervix may enrol . 2 . Active acute chronic infection , include , limited : upper airway infection , urinary tract infection , skin infection 3 . Use prescription medication within 14 day prior plan first drug administration throughout study . For FH subject statin therapy ( lipid lower therapy ) prohibit within 4 week prior first study drug administration . 4 . Use nonprescription overthecounter medication prohibit within 7 day prior plan first drug administration throughout study . This include vitamin , herbal supplement , remedy . An exception make medication supplement opinion investigator Sponsor complicate compromise study interfere study objective . 5 . Positive result follow Screening laboratory test : urine serum pregnancy test ( woman ) , alcohol breath test , urine drug abuse , hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>hyperlipidemia</keyword>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>PCSK9</keyword>
	<keyword>LNA-oligonucleotide</keyword>
</DOC>